通过基于变压器的模型提高阿尔茨海默病的分类,使用自主监督学习
M Priyadharshini1, V Murugesh2, Oleg Rybin3
1Department of Computer Science & Engineering, Faculty of Science and Technology (IcfaiTech), Foundation for Higher Education, ICFAI, Hyderabad, 501 203, India.
Scientific reports
|January 7, 2026
概括
一个新的增强型TabTransformer与自主监督学习 (ETT-SSL) 框架提高了使用唾液数据的阿尔茨海默病 (AD) 分类准确性. 这种可解释的方法达到95.8%的准确性,超过了传统的机器学习模型.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 生物医学信息学 生物医学信息学
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于昂贵和复杂的方法.
- 传统的机器学习 (ML) 模型在特征选择,类不平衡和AD分类的概括方面扎.
研究的目的:
- 引入一个带有自主监督学习 (ETT-SSL) 的增强型TabTransformer,用于准确和可解释的阿尔茨海默病分类.
- 开发一种使用唾液数据的临床实用诊断方法.
主要方法:
- 开发了一个ETT-SSL框架,集成了变压器架构和自我监督学习.
- 使用SHAP来选择特征,使用SMOTE来进行类平衡.
- 使用唾液数据进行分类.
主要成果:
- ETT-SSL实现了95.8%的高精度,显著优于基线模型 (SVM: 72.1%,RF: 78.3%,LightGBM: 80.5%) 和标准TabTransformer (85.2%).
- 该框架显示了更好的准确性和回忆力,减少了AD诊断中的错误负面.
- SHAP分析为临床决策提供了模型的解释性.
结论:
- 拟议的ETT-SSL框架提供了一种高度准确,可解释和临床实用的方法,用于使用唾液生物标志物的阿尔茨海默病诊断.
- 该方法可适应多模式数据集成 (例如MRI,基因组学,EHR) 以进一步提高诊断准确性和通用性.
相关概念视频
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
